ORC6: Implications for RNA-II Enzyme Research and Treatment (G23594)

Target Name: ORC6

NCBI ID: G23594

ORC6

ORC6: Implications for RNA-II Enzyme Research and Treatment

ORC6: TheORC6 (Origin Recognition Complex Subunit 6) is a protein that plays a crucial role in the process of origin recognition in the RNA polymerase II (RNA-II) enzyme. plays a key role in transcription. RNA-II enzyme is an important component of RNA polymerase II and is responsible for transcribing DNA templates into RNA. ORC6, a very active gene coding region, is involved in the origin recognition process of RNA-II enzymes.

The coding region of ORC6 consists of an open reading frame (ORF) and an N-terminal 伪-helix. ORF is a protein fragment with a length of 194 amino acids, which plays an important role in the origin recognition of RNA-II enzyme. The N-terminal 伪-helix is 鈥嬧?媋 secondary structure composed of 12 amino acids, which plays a key role in the catalytic activity of RNA-II enzyme.

Variations in the ORC6 gene are associated with the occurrence of various diseases. For example, variations in the ORC6 gene are associated with the occurrence of diseases such as Down's syndrome and Sjogren's syndrome. These diseases are all related to the abnormal expression of RNA-II enzyme, and ORC6 plays a key role in the identification of the origin of RNA-II enzyme. Therefore, variations in ORC6 are related to the occurrence of these diseases.

Inhibition of ORC6 will reduce the activity of RNA-II enzyme, resulting in abnormal gene expression. For example, inhibition of ORC6 can lead to reduced RNA-II enzyme activity in patients with Down syndrome, resulting in reduced immune function in patients. Therefore, inhibition of ORC6 may be a potential drug target.

Inhibition of ORC6 could also be used to treat diseases such as Stry-Joh syndrome. Stiff-Jow syndrome is a rare autoimmune disease characterized by the immune system attacking body tissue. RNA-II enzymes play an important role in these diseases, therefore, inhibition of ORC6 may be helpful in the treatment of these diseases.

Variations in the ORC6 gene are also associated with the occurrence of various cancers. For example, variations in the ORC6 gene are associated with the development of cancers such as colon, liver, and breast cancer. Therefore, inhibition of ORC6 may be of great significance in the treatment of these cancers.

ORC6 is an important gene coding region that plays a key role in the origin recognition process of RNA-II enzyme. Variations in ORC6 are associated with the occurrence of various diseases, therefore, inhibition of ORC6 may be helpful in the treatment of these diseases. In the future, research will continue to further investigate the role of ORC6 in RNA-II enzyme origin recognition and explore the potential of ORC6 inhibition in the treatment of these diseases.

Protein Name: Origin Recognition Complex Subunit 6

Functions: Component of the origin recognition complex (ORC) that binds origins of replication. DNA-binding is ATP-dependent. The specific DNA sequences that define origins of replication have not been identified yet. ORC is required to assemble the pre-replication complex necessary to initiate DNA replication. Does not bind histone H3 and H4 trimethylation marks H3K9me3, H3K27me3 and H4K20me3

The "ORC6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ORC6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets